OncoSec Medical to Present at Two Events in December
November 28 2014 - 6:02AM
Business Wire
OncoSec Medical Inc. (OTCQB: ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, will present at two
events in December. The Company’s agenda includes high-profile
scientific and investment conferences, coming on the heels of a
recent key milestone announcement.
LD Micro Conference
Jordyn Kopin, Associate Director of Corporate Communications,
will present a corporate overview of the Company at the 7th annual
LD Micro Conference, taking place December 2-4, 2014 at the Luxe
Sunset Boulevard Hotel in Los Angeles, California.
LD Micro is an investment newsletter firm that focuses on
finding undervalued companies in the micro-cap space. Since 2002,
the firm has published reports on select companies throughout the
year. The firm also hosts the LD Micro Invitational. It is a
non-registered investment advisor. For more information, please
contact 408-457-1042 or visit www.ldmicro.com.
Melanoma Bridge 2014
OncoSec Medical will present new data from clinical studies
evaluating the Company’s ImmunoPulse immunotherapy in patients with
melanoma at Melanoma Bridge 2014. The event is scheduled to take
place at the Royal Continental Hotel in Naples, Italy from December
3-6, 2014. For more information, click here.
Melanoma Bridge 2014 aims to achieve a broad-based participation
by various groups and societies sharing a clinical or basic
interest in the immunology and the biology of the cancer
microenvironment. The Scientific Board of Melanoma Bridge includes
well-known experts from around the world covering a variety of
different areas and specialties. The event is being jointly
organized by Istituto Nazionale Tumori Fondazione "G. Pascale",
Fondazione Melanoma Onlus and Sidra Medical and Research Center,
together with the Society for Immunotherapy of Cancer (SITC). For
more information, please visit: http://www.melanomabridge.org
About OncoSec Medical
OncoSec Medical Inc. is a biopharmaceutical company developing
its investigational ImmunoPulse intratumoral cancer immunotherapy.
OncoSec Medical's core technology is designed to
enhance the local delivery and uptake of DNA IL-12 and
other DNA-based immune-targeting agents. Clinical studies of
ImmunoPulse have demonstrated an acceptable safety profile and
preliminary evidence of anti-tumor activity in the treatment of
various skin cancers, as well as the potential to initiate a
systemic immune response without the systemic toxicities associated
with other treatments. OncoSec's lead program evaluating
ImmunoPulse for the treatment of metastatic melanoma is currently
in Phase 2 development, and is being conducted in collaboration
with several prominent academic medical centers. As the company
continues to evaluate ImmunoPulse in its current indications, it is
also focused on identifying and developing new immune-targeting
agents, investigating additional tumor indications, and evaluating
combination-based immunotherapy approaches. For more information,
please visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management’s current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical’s filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
Investor Relations:OncoSec Medical Inc.Jordyn Kopin,
855-662-6732investors@oncosec.comorPublic Relations:Dian Griesel
Int’l.Laura Radocaj, 212-825-3210lradocaj@dgicomm.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2023 to Apr 2024